LLYELI LILLY & Co

NYSE lilly.com


$ 919.83 $ 5.26 (0.58 %)    

Monday, 08-Jul-2024 14:11:19 EDT
QQQ $ 496.78 $ 0.25 (0.05 %)
DIA $ 393.36 $ -1.05 (-0.27 %)
SPY $ 555.00 $ 0.10 (0.02 %)
TLT $ 92.69 $ 0.26 (0.28 %)
GLD $ 217.92 $ -1.73 (-0.79 %)
$ 914.57
$ 915.71
$ 0.00 x 0
$ 920.09 x 102
$ 912.29 - $ 928.60
$ 431.12 - $ 918.50
2,880,863
na
826.59B
$ 0.57
$ 134.66
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-30-2024 03-31-2024 10-Q
2 02-21-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 04-27-2023 03-31-2023 10-Q
6 02-22-2023 12-31-2022 10-K
7 11-01-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 04-29-2022 03-31-2022 10-Q
10 02-23-2022 12-31-2021 10-K
11 10-27-2021 09-30-2021 10-Q
12 08-03-2021 06-30-2021 10-Q
13 04-30-2021 03-31-2021 10-Q
14 02-17-2021 12-31-2020 10-K
15 10-28-2020 09-30-2020 10-Q
16 07-31-2020 06-30-2020 10-Q
17 05-01-2020 03-31-2020 10-Q
18 02-19-2020 12-31-2019 10-K
19 10-25-2019 09-30-2019 10-Q
20 08-02-2019 06-30-2019 10-Q
21 05-02-2019 03-31-2019 10-Q
22 02-19-2019 12-31-2018 10-K
23 11-06-2018 09-30-2018 10-Q
24 07-25-2018 06-30-2018 10-Q
25 04-27-2018 03-31-2018 10-Q
26 02-20-2018 12-31-2017 10-K
27 10-27-2017 09-30-2017 10-Q
28 07-28-2017 06-30-2017 10-Q
29 05-01-2017 03-31-2017 10-Q
30 02-21-2017 12-31-2016 10-K
31 10-28-2016 09-30-2016 10-Q
32 07-28-2016 06-30-2016 10-Q
33 04-29-2016 03-31-2016 10-Q
34 02-19-2016 12-31-2015 10-K
35 10-30-2015 09-30-2015 10-Q
36 07-30-2015 06-30-2015 10-Q
37 04-30-2015 03-31-2015 10-Q
38 02-19-2015 12-31-2014 10-K
39 10-29-2014 09-30-2014 10-Q
40 07-28-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

https://www.forbes.com/sites/roberthart/2024/07/08/zepbound-sheds-more-weight-than-wegovy-study-finds/Eli Lilly's popular o...

 eli-lillys-first-biotech-deal-of-2024-buys-chronic-disease-player-morphic-for-32b

Eli Lilly to acquire Morphic Holding Inc for $3.2 billion, strengthening its portfolio in chronic disease treatments. Morphic&#...

 whats-going-on-with-eli-lilly-shares-friday

Eli Lilly and Co. (NYSE: LLY) shares are experiencing increased activity Friday afternoon. Here's what you need to know.

 glp-1-treatments-such-as-wegvoy-mounjaro-cut-obesity-related-cancer-risks-study-finds

A study finds that GLP-1 treatments, including Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, significantly reduce th...

Core News & Articles

https://news.bloomberglaw.com/health-law-and-business/ozempic-may-lower-risk-of-obesity-related-cancers-study-finds

 morgan-stanley-maintains-overweight-on-eli-lilly-and-co-maintains-1023-price-target

Morgan Stanley analyst Terence Flynn maintains Eli Lilly and Co (NYSE:LLY) with a Overweight and maintains $1023 price target.

 sp-500-nasdaq-100-climb-to-record-highs-as-data-fosters-rate-cut-optimism-ahead-of-fed-minutes-gold-bonds-rally-whats-driving-markets-wednesday

The S&P 500 and Nasdaq 100 indices surged to new all-time highs on Thursday, as investors heightened their expectations for...

 eli-lillys-alzheimers-therapys-broad-label-reflects-regulatory-confidence-in-anti-amyloid-antibodies-analyst

The FDA has approved Eli Lilly's Kisunla (donanemab) for early symptomatic Alzheimer's disease. Kisunla, targeting amyl...

Core News & Articles

https://www.statnews.com/2024/07/03/ozempic-wegovy-naion-vision-loss-study/A new observational study on Wednesday reported for ...

Core News & Articles

https://nypost.com/2024/07/03/lifestyle/potential-link-between-ozempic-wegovy-and-serious-eye-condition-study/Researchers say t...

 bmo-capital-maintains-outperform-on-eli-lilly-and-co-maintains-1001-price-target

BMO Capital analyst Evan Seigerman maintains Eli Lilly and Co (NYSE:LLY) with a Outperform and maintains $1001 price target.

 eli-lilly-shares-gain-after-drug-maker-gets-fdas-nod-for-early-alzheimers-treatment

The treatment is intended for adults in the early symptomatic stages of Alzheimer's disease.

 tesla-paramount-global-annovis-bio-eli-lilly-amazon-why-these-5-stocks-are-on-investors-radars-today

On Tuesday, the Dow Jones Industrial Average rose by 0.4%, closing at $39,331.85, while the S&P 500 also ended the day in p...